Zusammenfassung
Bei blasenbildenden Autoimmunerkrankungen kommt es durch Autoantikörperablagerung zu einer intra- oder subepidermalen Spaltbildung, die sich klinisch mit Blasen und sekundären Erosionen manifestiert. Eine Schleimhautbeteiligung ist häufig beim Pemphigus vulgaris und obligat beim vernarbenden Schleimhautpemphigoid. Seltener gehen bullöses Pemphigoid oder eine Epidermolysis bullosa acquisita mit einer Schleimhautbeteiligung einher. Für die Diagnose sind die Bestimmung der spezifisch abgelagerten Autoantikörper und das klinische Bild entscheidend. Die Therapie beruht auf einer Immunsuppression, die dem Typ der Erkrankung und der Schwere des Schleimhautbefalls angepasst werden muss. Zumindest die okuläre Beteiligung beim vernarbenden Schleimhautpemphigoid und der Pemphigus vulgaris erfordern eine systemische Therapie.
Abstract
Autoimmune bullous diseases are characterized by intraepidermal or subepidermal autoantibody deposition that leads to blisters and secondary erosion. Mucous membranes are frequently affected in pemphigus vulgaris and always involved in cicatricial and mucosal pemphigoid. Mucosal lesions are detected less frequently in patients with bullous pemphigoid or epidermolysis bullosa acquisita. The diagnosis of autoimmune bullous disorders is based on determination of the subtype of autoantibodies bound in the skin and the clinical picture. Treatment is based on immunosuppression related to the type of disease and severity of the mucosal symptoms. Ocular involvement in mucosal pemphigoid and pemphigus vulgaris requires systemic treatment.
Literatur
Gunther C, Beissert S (2015) Lupus erythematosus. Hautarzt 66(8):611–616. doi:10.1007/s00105-015-3644-7
Kneisel A, Hertl M (2011) Autoimmune bullous skin diseases. Part 1: Clinical manifestations. J Dtsch Dermatol Ges 9:844–856
Schmidt E, Zillikens D (2013) Pemphigoid diseases. Lancet 381:320–332
Kneisel A, Hertl M (2011) Autoimmune bullous skin diseases. Part 1: Clinical manifestations. J Dtsch Dermatol Ges 9:844–856
Culton DA, McCray SK, Park M et al (2015) Mucosal pemphigus vulgaris anti-Dsg3 IgG is pathogenic to the oral mucosa of humanized Dsg3 mice. J Invest Dermatol 135:1590–1597
Schmidt E, Goebeler M, Hertl M et al (2015) S2k guideline for the diagnosis of pemphigus vulgaris/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges 13:713–727
Shamsabadi RM, Basafa S, Yarahmadi R et al (2015) Elevated expression of NLRP1 and IPAF are related to oral pemphigus vulgaris pathogenesis. Inflammation 38:205–208
Eming R (2015) Pemphigus. Model disease for targeted therapy. Hautarzt 66:574–582
Hertl M, Eming R, Veldman C (2006) T cell control in autoimmune bullous skin disorders. J Clin Invest 116:1159–1166
Mayrshofer F, Hertl M, Sinkgraven R et al (2005) Significant decrease in quality of life in patients with pemphigus vulgaris. Results from the German Bullous Skin Disease (BSD) Study Group. J Dtsch Dermatol Ges 3:431–435
Boulard C, Duvert LS, Picard-Dahan C et al (2016) Calculation of cut-off values based on the ABSIS and PDAI pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. Br J Dermatol 175(1):142–149. doi:10.1111/bjd.14405
Maier L, Udvardi A, Hertl M et al (2016) Paraneoplastic pemphigus with anti-BP180 autoantibodies and Castleman’s disease. Br J Dermatol. doi:10.1111/bjd.14877
Nousari HC, Deterding R, Wojtczack H et al (1999) The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med 340:1406–1410
Li X, Qian H, Sogame R et al (2016) Integrin beta4 is a major target antigen in pure ocular mucous membrane pemphigoid. Eur J Dermatol 26:247–253
Sultan A, Stojanov IJ, Lerman MA et al (2015) Oral lichen planus pemphigoides: A series of four cases. Oral Surg Oral Med Oral Pathol Oral Radiol 120:58–68
Zillikens D, Caux F, Mascaro JM et al (1999) Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C‑terminal NC16A domain of BP180. J Invest Dermatol 113:117–121
Dainichi T, Koga H, Tsuji T et al (2010) From anti-p200 pemphigoid to anti-laminin gamma1 pemphigoid. J Dermatol 37:231–238
Alrashdan MS, Cirillo N, McCullough M (2016) Oral lichen planus: A literature review and update. Arch Dermatol Res. doi:10.1007/s00403-016-1667-2
Skaria M, Salomon D, Jaunin F et al (1999) IgG autoantibodies from a lichen planus pemphigoides patient recognize the NC16A domain of the bullous pemphigoid antigen 180. Dermatology 199:253–255
Burge SM, Frith PA, Juniper RP et al (1989) Mucosal involvement in systemic and chronic cutaneous lupus erythematosus. Br J Dermatol 121:727–741
Nico MM, Vilela MA, Rivitti EA et al (2008) Oral lesions in lupus erythematosus: Correlation with cutaneous lesions. Eur J Dermatol 18:376–381
Kneisel A, Hertl M (2011) Autoimmune bullous skin diseases. Part 2: Diagnosis and therapy. J Dtsch Dermatol Ges 9:927–947
Gunther C, Hertl M, Meurer M (2007) Diagnostic use of autoantibodies. Hautarzt 58:1063–1074
Gunther C, Wozel G, Meurer M et al (2004) Topical tacrolimus treatment for cicatricial pemphigoid. J Am Acad Dermatol 50:325–326
Eming R, Sticherling M, Hofmann SC et al (2015) S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges 13:833–844
Gunther C, Laske J, Frind A et al (2008) Successful therapy of pemphigus vulgaris with immunoadsorption using the TheraSorb adsorber. J Dtsch Dermatol Ges 6:661–663
Schmidt E, Zillikens D (2010) Immunoadsorption in dermatology. Arch Dermatol Res 302:241–253
Meyer-ter-Vehn T, Schmidt E, Zillikens D et al (2008) Mucous membrane pemphigoid with ocular involvement. Part II: Therapy. Ophthalmologe 105:405–419
Schulz S, Deuster D, Schmidt E et al (2011) Therapeutic effect of etanercept in anti-laminin 5 (laminin 332) mucous membrane pemphigoid. Int J Dermatol 50:1129–1131
Sobolewska B, Deuter C, Zierhut M (2013) Current medical treatment of ocular mucous membrane pemphigoid. Ocul Surf 11:259–266
Kasperkiewicz M, Zillikens D, Schmidt E (2012) Pemphigoid diseases: Pathogenesis, diagnosis, and treatment. Autoimmunity 45:55–70
Kasperkiewicz M, Zillikens D (2007) The pathophysiology of bullous pemphigoid. Clinic Rev Allerg Immunol 33:67–77
Danksagung
C. Günther erhielt eine Förderung der Deutschen Forschungsgemeinschaft (GU1212/1-1 und GU 1212/1-2).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
C. Günther gibt an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine vom Autor durchgeführten Studien an Menschen oder Tieren.
Rights and permissions
About this article
Cite this article
Günther, C. Schleimhautbeteiligung bei blasenbildenden Autoimmunerkrankungen. Hautarzt 67, 774–779 (2016). https://doi.org/10.1007/s00105-016-3871-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00105-016-3871-6